Journal of Hospice and Palliative Care

Korean Society for Hospice and Palliative Care (한국호스피스완화의료학회)
권호 표지
DOI QR코드

DOI QR Code

Treatment of Opioid Withdrawal Syndrome Triggered by Oxycodone/Naloxone with Dexmedetomidine

  • Se-Il, Go (Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine) ;
  • Jung Hoon, Kim (Department of Internal Medicine, Gyeongsang National University College of Medicine) ;
  • Jung Hun, Kang (Department of Internal Medicine, Gyeongsang National University College of Medicine)
  • Received : 2023.01.01
  • Accepted : 2023.02.07
  • Published : 2023.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

The combination of oxycodone and naloxone is useful for cancer pain management. Naloxone, as a pure opioid antagonist, cannot be used simultaneously with opioids. However, owing to its low bioavailability, it can be used in an oral composite formulation. We present the case of a 55-year-old man with gastric cancer who experienced severe opioid withdrawal syndrome (OWS) triggered by oxycodone/naloxone that was successfully managed with dexmedetomidine. He had been in a stable condition on intravenous morphine to alleviate cancer pain. Intravenous morphine was switched to oral oxycodone/naloxone for discharge from the hospital. The patient suddenly developed restlessness, heartburn, and violent behavior 30 minutes after taking oxycodone/naloxone. We attempted sedation with midazolam and propofol, but paradoxical agitation and desaturation occurred. Next, we tried dexmedetomidine and the patient showed a decreased heart rate and reduced agitation. The patient was eventually stabilized by increasing the dose of dexmedetomidine. This report informs clinicians of the possibility of OWS when switching from opioids to oxycodone/naloxone, which can be overcome with the appropriate use of sedatives and dexmedetomidine depending on the patient's condition.

Keywords

References

  1. Reid CM, Martin RM, Sterne JA, Davies AN, Hanks GW. Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:837-43. https://doi.org/10.1001/archinte.166.8.837
  2. Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012;26:50-60. https://doi.org/10.1177/0269216311418869
  3. Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K. Oral naloxone reverses opioid-associated constipation. Pain 2000;84:105-9. https://doi.org/10.1016/S0304-3959(99)00185-2
  4. Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther 2012;50:360-7. https://doi.org/10.5414/CP201646
  5. Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf 2018;9:63-88. https://doi.org/10.1177/2042098617744161
  6. Wong A, Macleod D, Robinson J, Koutsogiannis Z, Graudins A, Greene SL. Oxycodone/naloxone preparation can cause acute withdrawal symptoms when misused parenterally or taken orally. Clin Toxicol (Phila) 2015;53:815-8. https://doi.org/10.3109/15563650.2015.1060486
  7. Kim JH, Song H, Lee G-W, Kang JH. Opioid withdrawal symptoms after conversion to oral oxycodone/naloxone in advanced cancer patients receiving strong opioids. Korean J Hosp Palliat Care 2017;20:131-5. https://doi.org/10.14475/kjhpc.2017.20.2.131
  8. Kang JH, Lee GW, Shin SH, Bruera E. Opioid withdrawal syndrome after treatment with low-dose extended-release oxycodone and naloxone in a gastric cancer patient with portal vein thrombosis. J Pain Symptom Manage 2013;46:e15-7. https://doi.org/10.1016/j.jpainsymman.2013.02.009
  9. Vanden Hoek TL, Morrison LJ, Shuster M, Donnino M, Sinz E, Lavonas EJ, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010;122:S829-61. https://doi.org/10.1161/CIRCULATIONAHA.110.971069
  10. Bellingan M. What drug?: Naloxone. Australian Pharmacist 2017;36:54-7.
  11. Pergolizzi JV Jr, Raffa RB, Rosenblatt MH. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. J Clin Pharm Ther 2020;45:892-903. https://doi.org/10.1111/jcpt.13114
  12. Yu E, Miotto K, Akerele E, Montgomery A, Elkashef A, Walsh R, et al. A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug Alcohol Depend 2008;97:158-68. https://doi.org/10.1016/j.drugalcdep.2008.04.002
  13. Gowing L, Farrell MF, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2014;CD002024.
  14. Jung S, Rosini JM. Dexmedetomidine for treatment of refractory heroin withdrawal. J Emerg Nurs 2017;43:182-4. https://doi.org/10.1016/j.jen.2017.01.004